QMDT (QMDT) Stock Price & Analysis

QMDT (QMDT) rose 0.00% to USD 0 as of June 10, 2026 at 13:02 UTC, according to Nexqual real-time market data.

QMDT last closed at USD 0; the session ranged USD 0–0 on volume of 135,000 shares. Market capitalization is $29,876, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 13:02 UTC.

Key Statistics (as of June 10, 2026 at 13:02 UTC)

PriceUSD 0
Change▲ 0.00% (up)
Previous CloseUSD 0
OpenUSD 0
Day RangeUSD 0 – 0
52-Week RangeUSD 0 – 0
Volume135,000 shares
Market Cap$29,876
ExchangePNK

Technical Analysis (QMDT)

Nexqual's technical model rates QMDT "NEUTRAL" based on 3 bullish and 3 bearish signals across 124 daily candles, as of June 10, 2026 at 13:02 UTC.

Overall SignalNEUTRAL
RSI (14)100 (overbought)
vs SMA50Above (USD 0)
MACD0 (positive)

Analyst Ratings (QMDT)

Wall Street analysts rate QMDT "None", per Nexqual as of June 10, 2026 at 13:02 UTC.

Consensus RatingNone

Earnings (QMDT)

Recent Earnings History

QuarterActual vs Estimate
2011-12-31USD -0.01 vs est -0.01 ▲ beat
2011-09-30USD -0.01 vs est -0.01 ▲ beat
2011-06-30USD -0.03 vs est -0.01 ▼ miss

Source: Nexqual, June 10, 2026 at 13:02 UTC.

Financials & Fundamentals (QMDT)

Total Revenue$928,493
Revenue Growth (YoY)-27.40%
Gross Margin+13.80%
Operating Margin-77.01%
Profit Margin-76.80%
Current Ratio0.04
Total Cash$49,677
Total Debt$7.91M
Free Cash Flow$-1.29M

Source: Nexqual, June 10, 2026 at 13:02 UTC.

Financial Health Score (QMDT)

Nexqual rates QMDT's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 13:02 UTC.

GrowthCritical — Revenue -27% YoY (latest Q), sharp decline
ProfitabilityWeak — Not yet profitable — scaling phase
Balance SheetMixed — $50K cash vs $8M debt
Cash FlowWeak — FCF negative: -$1M, burning cash
EfficiencyMixed — No data

Ownership (QMDT)

Insider Ownership+0.00%
Institutional Ownership+0.00%
Shares Outstanding37.35M

Source: Nexqual, June 10, 2026 at 13:02 UTC.

Leadership (QMDT)

QMDT is led by Gregory S. Schultz (age 75), Chairman & Scientific Advisor, per Nexqual as of June 10, 2026 at 13:02 UTC.

Chairman & Scientific AdvisorGregory S. Schultz (age 75)
Principal Executive Officer, President & DirectorBernd Liesenfeld (age 55)

Peers & Related Stocks

SymbolNamePriceChange
NPHCNutra Pharma Corp.USD 0▲ 0%
RGINREGENICIN INCUSD 0▲ 0%
AOLSAEOLUS PHARMACEUTICALS INCUSD 0▲ 0%
HMGNHEMAGEN DIAGNOSTICS INCUSD 0▲ 0%
IYXIINYX INCUSD 0▲ 0%

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 13:02 UTC. This page is informational and not investment advice.